Tissue inhibitor of metalloproteinase-1 and-3 improves cardiac function in an ischemic cardiomyopathy model rat

Tissue Engineering - Part A

Volumn 20, Issue 21-22, 2014, Pages 3073-3084

  Uchinaka, Ayako ^a   Kawaguchi, Naomasa ^a   Mori, Seiji ^a   Hamada, Yoshinosuke ^a   Miyagawa, Shigeru ^a   Saito, Atsuhiro ^b   Sawa, Yoshiki ^a   Matsuura, Nariaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CELL CULTURE; CELL DEATH; COLLAGEN; DISEASES; GELS; MUSCLE; PHOSPHORYLATION; RATS;

CARDIAC HYPERTROPHY; CARDIAC REGENERATION; CARDIOPROTECTIVE EFFECT; INDEPENDENT FUNCTIONS; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; SMOOTH MUSCLE ACTINS; TRANSFORMING GROWTH FACTORS;

HEART;

COLLAGEN GEL; FOCAL ADHESION KINASE; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR; SMAD3 PROTEIN; SMOOTH MUSCLE ACTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; CARDIOTONIC AGENT; DRUG IMPLANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HEART FUNCTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IN VITRO STUDY; ISCHEMIC CARDIOMYOPATHY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; CARDIOMYOPATHIES; COMPLICATION; CONVALESCENCE; DRUG EFFECTS; DRUG IMPLANT; HEART VENTRICLE REMODELING; MYOCARDIAL ISCHEMIA; PATHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DRUG IMPLANTS; MALE; MYOCARDIAL ISCHEMIA; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84909943426     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0763     Document Type: Article

References (31)

1. Creemers, E.E., Davis, J.N., Parkhurst, A.M., Leenders, P., Dowdy, K.B., Hapke, E., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284, H364, 2003.
2. Heymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5, 1135, 1999.
3. Heymans, S., Pauschinger, M., De, Palma, A., Kallwellis-Opara, A., Rutschow, S., Swinnen, M., et al. Inhibition of urokinase-type plasminogen activator or matrix metallo-proteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114, 565, 2006.
4. Matsumura, S., Iwanaga, S., Mochizuki, S., Okamoto, H., Ogawa, S., and Okada, Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115, 599, 2005.
5. Heymans, S., Lupu, F., Terclavers, S., Vanwetswinkel, B., Herbert, J.M., Baker, A., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166, 15, 2005.
6. Lovelock, J.D., Baker, A.H., Gao, F., Dong, J.F., Bergeron, A.L., McPheat, W., et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibro-blasts. Am J Physiol Heart Circ Physiol 288, H461, 2005.
7. Brew, K., Dinakarpandian, D., and Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477, 267, 2000.
8. Takatani, T., Takahashi, K., Uozumi, Y., Shikata, E., Ya-mamoto, Y., Ito, T., et al. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol Cell Physiol 287, C949, 2004.
9. Yamamoto, M., Takahashi, Y., and Tabata, Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomater-ials 24, 4375, 2003.
10. Tabata, Y., Nagano, A., and Ikada, Y. Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Eng 5, 127, 1999.
11. Torsoni, A.S., Constancio, S.S., Nadruz, W., Jr., Hanks, S.K., and Franchini, K.G. Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes. Circ Res 93, 140, 2003.
12. Nadruz, W., Jr., Corat, M.A., Marin, T.M., Guimaraes, Pereira, G.A., and Franchini, K.G. Focal adhesion kinase mediates MEF2 and c-Jun activation by stretch: role in the activation of the cardiac hypertrophic genetic program. Cardiovasc Res 68, 87, 2005.
13. Baba, H.A., Stypmann, J., Grabellus, F., Kirchhof, P., Sokoll, A., Schafers, M., et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 59, 390, 2003.
14. Hinz, B., Celetta, G, Tomasek, J.J., Gabbiani, G, and Cha-ponnier, C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 12, 2730, 2001.
15. Hinz, B., Mastrangelo, D., Iselin, C.E., Chaponnier, C, and Gabbiani, G. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 159, 1009, 2001.
16. Dobaczewski, M., Bujak, M., Li, N., Gonzalez-Quesada, C, Mendoza, L.H., Wang, X.F., et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing. Circ Res 107, 418, 2010.
17. Woessner, J.F., Jr. That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin Invest 108, 799, 2001.
18. Fedak, P.W., Altamentova, S.M., Weisel, R.D., Nili, N, Ohno, N., Verma, S., et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol 284, H626, 2003.
19. Wisniewska, M., Goettig, P., Maskos, K., Belouski, E., Winters, D., Hecht, R., et al. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol 381, 1307, 2008.
20. Satoh, M., Nakamura, M., Saitoh, H., Satoh, H, Maesawa, C, Segawa, I., et al. Tumor necrosis factor-converting enzyme and tumor necrosis factor-A in human dilated cardiomyopathy. Circulation 99, 3260, 1999.
21. Baranek, T., Debret, R., Antonicelli, F., Lamkhioued, B., Belaaouaj, A., Hornebeck, W., et al. Elastin receptor (spliced galactosidase) occupancy by elastin peptides counteracts proinflammatory cytokine expression in lipopolysaccharide-stimulated human monocytes through NF-kappaB down-regulation. J Immunol 179, 6184, 2007.
22. Kothapalli, C.R., and Ramamurthi, A. Induced elastin regeneration by chronically activated smooth muscle cells for targeted aneurysm repair. Acta Biomater 6, 170, 2010.
23. Uchinaka, A., Kawaguchi, N., Hamada, Y., Miyagawa, S., Saito, A., Mori, S., et al. Transplantation of elastin-secreting myoblast sheets improves cardiac function in infarcted rat heart. Mol Cell Biochem 368, 203, 2012.
24. Hammoud, L., Burger, D.E., Lu, X, and Feng, Q. Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling. Am J Physiol Cell Physiol 296, C735, 2009.
25. Hammoud, L., Xiang, F., Lu, X., Brunner, F., Leco, K., and Feng, Q. Endothelial nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting tissue inhibitor of metalloproteinase-3 expression. Cardiovasc Res 75, 359, 2007.
26. Kang, K.H., Park, S.Y., Rho, S.B., and Lee, J.H. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc Res 79, 150, 2008.
27. Fedak, P.W., Smookler, D.S., Kassiri, Z., Ohno, N., Leco, K.J., Verma, S., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110, 2401, 2004.
28. Senbonmatsu, T., Saito, T., Landon, E.J., Watanabe, O., Price, E., Jr., Roberts, R.L., et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J 22, 6471, 2003.
29. Widdop, R.E., Jones, E.S., Hannan, R.E., and Gaspari, T.A. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 140, 809, 2003.
30. Glass, C., and Singla, D.K. Overexpression of TIMP-1 in embryonic stem cells attenuates adverse cardiac remodeling following myocardial infarction. Cell Transplant 21, 1931, 2012.
31. Boulday, G., Fitau, J., Coupel, S., Soulillou, J.P., and Charreau, B. Exogenous tissue inhibitor of metalloprotei-nase-1 promotes endothelial cell survival through activation of the phosphatidylinositol 3-kinase/Akt pathway. Ann N Y Acad Sci 1030, 28, 2004.